[Date]
[Payer
n ame]
ATTN:
A PPEALS
[Payer
c ontact
n ame]
[Payer
a
ddress]
Patient:
[ Patient’s
f irst
a nd
l ast
n
ame]
Subscriber
I D#:
[ Insurance
I D
# ]
Subscriber
G roup
# :
[ Insurance
g roup
#
]
Re:
C OTELLIC®
( cobimetinib)
t ablets
Dates
o f
S ervice:
[ Include
a ll
d enied
d ates
o f
s
ervice]
Dear
A ppeals
R eviewer:
I
a m
w riting
t o
r equest
[
appeal/redetermination/reconsideration]
o f
t he
a bove
d enial(s)
o f
COTELLIC®
( cobimetinib)
t ablets
f or
m y
p atient
[ patient
n
ame].
I
u nderstand
f rom
y our
denial
l etter
t hat
t he
d enials
w ere
b ased
o n
[ denial
r
eason].
I
w ould
l ike
t o
a ddress
[ that
reason/those
r
easons]
n ow.
I
w ould
a ppreciate
a
p rompt
r eview
o f
t he
e nclosed
information
d emonstrating
m edical
n ecessity
a nd
c overage
f or
C OTELLIC.
Patient’s
C linical
H istory
[Patient’s
n
ame]
i s
a
[
age]
y ear
o ld
[
male/female]
w ho
w as
d iagnosed
o n
[
date]
w ith
s tage
[IIIC/
I
V]
m etastatic
m elanoma.
T reatment
o ptions
f or
p atients
w ith
m etastatic
m elanoma
are
l
imited.
[
He/She]
u nderwent
[ describe
t reatment
t o
d
ate].
[Include
d iagnosis
a nd
d ates]
•
[Past
t reatments]
•
[Test
r esults
t hat
i ndicate
f ailure
o f
p ast
t reatment]
•
[Extenuating
c ircumstances
t hat
w ould
p reclude
a lternatives
t o
C OTELLIC]
•
[Social
&
f amily
i nformation]
•
[REMINDER:
I f
a
p ayer
h as
a
p ublished
p olicy,
i nclude
h ere]
[REMINDER:
I f
s tate
s tatute
e xists,
i nclude
h ere]
Treatment
P lan
On
1 1/10/2015,
t he
F DA
a pproved
t he
u se
o f
C OTELLIC
f or
t he
t reatment
o f
p atients
w ith
unresectable
o r
m etastatic
m elanoma
w ith
B RAF
V 600E
o r
V 600K
m utation,
i n
c ombination
with
v emurafenib.
[Include
p lan
o f
t reatment
( dosage,
l ength
o f
t reatment),
F DA
A pproval
L etter,
r elevant
journal
a rticles,
c linical
s tudies,
a nd
c linical
p ractice
g uidelines
t hat
s upport
t he
u se
o f
COTELLIC.
C onsider
m entioning
e xperts
i n
t he
f ield
w ho
a lso
s upport
t he
t reatment.]
Summary
In
s ummary,
I
a m
r equesting
[ appeal/
r edetermination/
r
econsideration]
o f
t he
d enial(s)
o f
COTELLIC
t herapy
f or
m y
p atient,
[ Patient
N
ame].
[ He/
S
he]
w as
d iagnosed
w ith
unresectable
s tage
[ IIIC/
I
V]
m elanoma
w hich
i s
p ositive
f or
t he
B RAF
V 600
m utation;
a
life-‐threatening
m elanoma
w ith
f ew
t reatment
o ptions.
I
a m
r equesting
t hat
y ou
r econsider
coverage
b ased
o n
t he
i nformation
a bove.
I
a m
r eadily
a vailable
a t
m y
o ffice
p hone
[ MD
ACS/030915/0032